Clonidine extended-release: in attention-deficit hyperactivity disorder.

  title={Clonidine extended-release: in attention-deficit hyperactivity disorder.},
  author={Jamie D. Croxtall},
  journal={Paediatric drugs},
  volume={13 5},
Clonidine, an α(2)-adrenergic agonist, is approved in the US as an extended-release (XR) tablet for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two, randomized, double-blind, multicenter, phase III trials of 8 weeks' duration, clonidine XR improved the symptoms of ADHD in children and adolescents. Significantly greater reductions from baseline in ADHD rating scale IV (ADHD-RS-IV) total scores at week 5 (primary endpoint… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-8 of 8 extracted citations

Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).

The journal of the American Academy of Psychiatry and the Law • 2016
View 2 Excerpts

Pharmacokinetic evaluation of eltoprazine.

Expert opinion on drug metabolism & toxicology • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…